Literature DB >> 7858067

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

R W Buchanan1, C Holstein, A Breier.   

Abstract

Previous studies have suggested that clozapine may improve neuropsychological test performance. The current study was designed to examine the comparative efficacy and the long-term effect of clozapine (versus haloperidol), on neuropsychological test performance. Neuropsychological measures of executive/attention, visuospatial, and memory function were administered to schizophrenic patients at baseline, at the end of a 10-week double-blind study, and after 1 year of open clozapine treatment. Symptoms and function ratings were obtained at the same time points. The 10-week double-blind study revealed significant group-by-time interactions for two measures: Categorical Fluency and WAIS-R Block Design. At the end of 1 year of open treatment there were significant improvements in Verbal Fluency, Mooney Faces Closure, and WAIS-R Block Design performance, and trend improvements in Stroop Color-Word Interference, Category Fluency, and WMS-R Logical Memory performance. Improvements in neuropsychological performance were unrelated to symptom changes. Change in selected neuropsychological measures were significantly correlated with improvement in quality of life. The results suggest that long-term clozapine treatment may have beneficial effects on a broad range of cognitive functions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858067     DOI: 10.1016/0006-3223(94)90082-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  30 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 2.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

3.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.

Authors:  Philip D Harvey; Michael F Green; Susan R McGurk; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

Review 4.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

5.  Cognitive effects of olanzapine treatment in schizophrenia.

Authors:  Susan R McGurk; M A Lee; K Jayathilake; Herbert Y Meltzer
Journal:  MedGenMed       Date:  2004-05-10

Review 6.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

7.  Clinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong Kong.

Authors:  Frederick Ka Ching Yeung; Sunny Ho Wan Chan
Journal:  Qual Life Res       Date:  2006-09-07       Impact factor: 4.147

8.  Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.

Authors:  Ee Peng Lim; Vivek Verma; Rajini Nagarajah; Gavin S Dawe
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

9.  Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Authors:  Tonmoy Sharma; Catherine Hughes; William Soni; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

Review 10.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.